NEW YORK, Aug. 22, 2023 (GLOBE NEWSWIRE) — The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Apellis Pharmaceuticals, Inc. APLS alleging that the Company violated federal securities laws.
Class Period: January 28, 2021 to July 28, 2023
Lead Plaintiff Deadline: October 2, 2023
No obligation or cost to you.
Learn more about your recoverable losses in APLS:
https://www.kleinstocklaw.com/pslra-1/apellis-lawsuit-loss-submission-form?id=44198&from=3
Apellis Pharmaceuticals, Inc. NEWS – APLS NEWS
CLASS ACTION CASE DETAILS: The filed complaint alleges that Apellis Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the design of SYFOVRE’s clinical trials was insufficient to identify incidents of retinal vasculitis in patients receiving SYFOVRE injections; (2) as a result, the commercial adoption of SYFOVRE was subject to significant, unknown risk factors; and (3) therefore, defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis.
WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Apellis you have until October 2, 2023 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
NO COST TO YOU: If you purchased Apellis securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.
HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the APLS lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link: https://www.kleinstocklaw.com/pslra-1/apellis-lawsuit-loss-submission-form?id=44198&from=3.
ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas…
